LEAFBIO
LIVE

Serial Number

85710504

Owner

LeafBio, Inc.

Attorney

Paul Nardulli

First Use Date

Jan 1, 2013

Filing Date

Aug 22, 2012

Add to watchlist:

No watchlists yet
View on USPTO

LEAFBIO Trademark

Serial Number: 85710504 • Registration: 4969019

LEAFBIO is a trademark filed by LeafBio, Inc. on August 22, 2012. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

LeafBio, Inc. (2 trademarks)

San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

August 22, 2012

Registration Date

May 31, 2016

First Use Anywhere

January 1, 2013

First Use in Commerce

January 1, 2013

Published for Opposition

January 29, 2013

Goods & Services

Pharmaceutical products for use in the treatment and prevention of [ cardiovascular diseases and disorders, central nervous system and neurological diseases and disorders, urological diseases and disorders, ] viral and infectious diseases, [ cancer, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, migraines and headaches, pain, hypertension, ] inflammation and inflammatory diseases and disorders, [ metabolic diseases and disorders, ] respiratory and infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, [ psychiatric diseases and disorders, asthma, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, ] sexually transmitted infections including, but not limited to, HIV, HPV, and herpes [, and hemolytic diseases and disorders; Pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, urological preparations, ophthalmologic preparations, tissue and skin repair preparations and gynecological preparations ] ; Pharmaceuticals, namely, anti-infectives; [ Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids, including for microorganisms; Drug delivery agents consisting of compounds that facility delivery of a wide range of pharmaceuticals; ] Antibacterial pharmaceuticals; [ Cardiovascular pharmaceuticals; ] Contraceptive foams, sponges, preparations; [ Oral contraceptives; ] Pharmaceutical products for use in biodefense

Diagnostic reagents for scientific or research use; [ Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs; ] Diagnostic reagents for clinical or medical laboratory use; [ Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; ] Diagnostic reagents for scientific or research use; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; [ Reagent for chemical analysis; ] Reagents for research purposes; Reagents for scientific or medical research use; [ Reagents for testing the sterility of pharmaceuticals and injectable solutions; ] Reagents for use in scientific apparatus for chemical or biological analysis; Reagents for use in biodefense

Pharmaceutical research and development; research and development of pharmaceutical preparations for the treatment and prevention of [ cardiovascular diseases and disorders, central nervous system and neurological diseases and disorders, ] viral and infectious diseases, [ cancer, urological diseases and disorders, ] gastrointestinal diseases and disorders, [ musculoskeletal diseases and disorders, migraines and headaches, pain, hypertension, ] inflammation and inflammatory diseases and disorders, [ metabolic diseases and disorders, ] respiratory and infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, [ psychiatric diseases and disorders, asthma, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, ] sexually transmitted infections including, but not limited to, HIV, HPV, and herpes [ and hemolytic diseases and disorders; research and development of pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, urological preparations, ophthalmologic preparations, tissue and skin repair preparations and gynecological preparations ] ; research and development of drug delivery devices; medical and scientific research, namely, conducting clinical trials; Consulting services in the fields of biotechnology, pharmaceutical research and development, [ laboratory testing, diagnostics, ] and pharmacogenetics; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development; Pharmaceutical research and development services; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; [ Providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; ] Pharmaceutical research and development in relation to biodefense

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jun 1, 2025 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Nov 30, 2022 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Nov 30, 2022 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 17, 2022 APRE
TEAS SECTION 8 & 15 RECEIVED
May 12, 2022 E815
REGISTERED-PRINCIPAL REGISTER
May 31, 2016 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE MAILED
Apr 26, 2016 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 23, 2016 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 16, 2016 SUPC
USE AMENDMENT FILED
Mar 17, 2016 IUAF
TEAS STATEMENT OF USE RECEIVED
Mar 17, 2016 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Sep 29, 2015 EXRA
SOU EXTENSION 5 GRANTED
Sep 27, 2015 EX5G
SOU EXTENSION 5 FILED
Sep 9, 2015 EXT5
SOU TEAS EXTENSION RECEIVED
Sep 9, 2015 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Apr 4, 2015 EXRA
SOU EXTENSION 4 GRANTED
Apr 3, 2015 EX4G
SOU EXTENSION 4 FILED
Mar 20, 2015 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 20, 2015 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Oct 2, 2014 EXRA
SOU EXTENSION 3 GRANTED
Oct 1, 2014 EX3G
SOU EXTENSION 3 FILED
Sep 19, 2014 EXT3
SOU TEAS EXTENSION RECEIVED
Sep 19, 2014 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 3, 2014 TCCA
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Apr 18, 2014 EXRA
SOU EXTENSION 2 GRANTED
Apr 17, 2014 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 14, 2014 AITU
SOU EXTENSION 2 FILED
Mar 20, 2014 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 20, 2014 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Sep 26, 2013 EXRA
SOU EXTENSION 1 GRANTED
Sep 24, 2013 EX1G
SOU EXTENSION 1 FILED
Sep 24, 2013 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 24, 2013 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Mar 26, 2013 NOAM
PUBLISHED FOR OPPOSITION
Jan 29, 2013 PUBO
NOTICE OF PUBLICATION
Jan 9, 2013 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 17, 2012 CNSA
ASSIGNED TO EXAMINER
Dec 15, 2012 DOCK
NOTICE OF PSEUDO MARK MAILED
Aug 31, 2012 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 30, 2012 NWOS
NEW APPLICATION ENTERED
Aug 25, 2012 NWAP